Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Khateb, Mamduh ^a   Ruimi, Nili ^a   Khamisie, Hazem ^a   Najajreh, Yousef ^b   Mian, Afsar ^c   Metodieva, Anna ^c   Ruthardt, Martin ^c   Mahajna, Jamal ^a,d  

^a Galilee Technology Center   (Israel)

^b AL QUDS UNIVERSITY   (Palestine)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d TEL HAI COLLEGE   (Israel)

Author keywords

" gatekeeper" mutation T315I; Abl kinase inhibitors; Allosteric inhibition; Bcr Abl; Philadelphia chromosome

Indexed keywords

ABELSON KINASE; ALPHA TUBULIN; BCR ABL PROTEIN; DASATINIB; GNF 2; IMATINIB; JANUS KINASE 2; NILOTINIB; PROTEIN KINASE INHIBITOR; STAT5A PROTEIN; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL CULTURE; CELL COUNT; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; INHIBITION KINETICS; LEUKEMIA; MOUSE; NONHUMAN; PHILADELPHIA CHROMOSOME POSITIVE CELL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG THERAPY, COMBINATION; FUSION PROTEINS, BCR-ABL; GENES, ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 84869878739     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-563     Document Type: Article

References (14)

1. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Neuberg D, Wright RD, Gilliland DG, Griffin JD. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7:129-141. 10.1016/j.ccr.2005.01.007, 15710326.
2. Olivieri A, Manzione L. Dasatinib: a new step in molecular target therapy. Ann Oncol 2007, 18(Suppl 6):vi42-vi46.
3. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002, 62:4236-4243.
4. Adrian FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y, Zhang G, Hur W, Ding S, Manley P, Mestan J, Fabbro D, Gray NS. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol 2006, 2:95-102. 10.1038/nchembio760, 16415863.
5. Zhang J, Adrian FJ, Jahnke W, Cowan-Jacob SW, Li AG, Iacob RE, Sim T, Powers J, Dierks C, Sun F, Guo GR, Ding Q, Okram B, Choi Y, Wojciechowski A, Deng X, Liu G, Fendrich G, Strauss A, Vajpai N, Grzesiek S, Tuntland T, Liu Y, Bursulaya B, Azam M, Manley PW, Engen JR, Daley GQ, Warmuth M, Gray NS. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 2010, 463:501-506. 10.1038/nature08675, 2901986, 20072125.
6. Fabbro D, Manley PW, Jahnke W, Liebetanz J, Szyttenholm A, Fendrich G, Strauss A, Zhang J, Gray NS, Adrian F, Warmuth M, Pelle X, Grotzfeld R, Berst F, Marzinzik A, Cowan-Jacob SW, Furet P, Mestan J. Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site. Biochim Biophys Acta 2010, 1804:454-462. 10.1016/j.bbapap.2009.12.009, 20152788.
7. Yassin M, Wasser SP, Mahajna J. Substances from the medicinal mushroom Daedalea gibbosa inhibit kinase activity of native and T315I mutated Bcr-Abl. Int J Oncol 2008, 32:1197-1204.
8. Mian AA, Metodieva A, Najajreh Y, Ottmann OG, Mahajna J, Ruthardt M. p185BCR/ABL has a lower sensitivity than p210BCR/ABL to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia. Haematologica 2012, 97:251-257. 10.3324/haematol.2011.047191, 3269486, 22058195.
9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
10. Choi HG, Ren P, Adrian F, Sun F, Lee HS, Wang X, Ding Q, Zhang G, Xie Y, Zhang J, Liu Y, Tuntland T, Warmuth M, Manley PW, Mestan J, Gray NS, Sim T. A Type-II Kinase Inhibitor Capable of Inhibiting the T315I "Gatekeeper" Mutant of Bcr-Abl. J Med Chem 2010, 53:5439-5448. 10.1021/jm901808w, 20604564.
11. Mian AA, Oancea C, Zhao Z, Ottmann OG, Ruthardt M. Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL. Leukemia 2009, 23:2242-2247. 10.1038/leu.2009.194, 19798092.
12. Mian A, Metodieva A, Badura S, Khateb M, Ruimi N, Najajreh Y, Ottmann GO, Mahajna J, Ruthardt M. GNF-2 enhances the efficacy of AKIs to inhibit unmutated BCR-ABL and BCR-ABL-T315I. BMC Cancer 2012, 12:411. 10.1186/1471-2407-12-411, 3488316, 22985168.
13. Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB, Terrell S, Klitgaard JL, Santo L, Addorio MR, Ebert BL, Griffin JD, Frank DA. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 2011, 117:3421-3429. 10.1182/blood-2009-11-255232, 3069678, 21233313.
14. Okutani Y, Kitanaka A, Tanaka T, Kamano H, Ohnishi H, Kubota Y, Ishida T, Takahara J. Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway. Oncogene 2001, 20:6643-6650. 10.1038/sj.onc.1204807, 11641791.